Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- CFTR protein and its mutations in CF patients
- Mislocalization of deltaF508 CFTR
- Consequences of defects in CFTR function
- CFTR activity correlates with CF severity
- Cystic fibrosis foundation therapeutics pipeline
- CF and CFTR folding/degradation
- Role of chaperones in CFTR biogenesis
- Results of calnexin inactivation
- Results of Hsc70 inactivation
- Regulation of Hsp70 function by Hsp40
- Type I Hsp40 proteins contain a CAAX box
- Steps in the CFTR folding pathway
- Does Hsc70 facilitate CFTR degradation?
- U-box family
- Results of CHIP overexpression
- CHIP expression blocks CFTR processing
- CHIP mediated triage of misfolded proteins
- CFTR-deltaF508 partitioning between pathways
- RMA1 is an ER localized RING E3
- Elevation of Rma1 levels blocks CFTR folding
- Results of Rma1 and Ubc6e reduction
- E2/E3 ubiquitin ligase senses folded CFTR
- Derlin-1 protein
- Results of DER1 overexpression
- Results of DER1 knockdown
- Possible role of DER1
- CFTR-deltaF508 sensitivity to Rma1 changes
- Regions recognized by Rma1 and CHIP E3
- Sensing delta-F508 folding defects
- CFTR sub-domains recognition by Rma1/CHIP
- Small molecules and CFTR folding efficiency
- Results of treatment with VRT-532 and Corr4a
- Recognition of CFTR-deltaF508 folding defects
- Acknowledgements
Topics Covered
- Cystic fibrosis is a fatal homozygous recessive disorder
- Caused primarily by misfolding of mutant forms of cystic fibrosis transmembrane conductance regulator (CFTR)
- The folding defects in mutant CFTR are detected by protein quality control machines in the endoplasmic reticulum that target mutant CFTR for premature degradation
- Small molecules that are being developed as drugs to treat cystic fibrosis enable mutant CFTR to avoid recognition by the endoplasmic reticulum quality control system and function at the cell surface
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cyr, D.M. (2007, October 1). Roles for molecular chaperones in cystic fibrosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/TWBR5163.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Douglas M. Cyr has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.